Association between genotypic diversity and biofilm production in group B Streptococcus by Parker, Robert E. et al.
RESEARCH ARTICLE Open Access
Association between genotypic diversity
and biofilm production in group B
Streptococcus
Robert E. Parker1, Clare Laut1, Jennifer A. Gaddy2,3, Ruth N. Zadoks4,5, H. Dele Davies6 and Shannon D. Manning1*
Abstract
Background: Group B Streptococcus (GBS) is a leading cause of sepsis and meningitis and an important factor in
premature and stillbirths. Biofilm production has been suggested to be important for GBS pathogenesis alongside
many other elements, including phylogenetic lineage and virulence factors, such as pili and capsule type. A
complete understanding of the confluence of these components, however, is lacking. To identify associations
between biofilm phenotype, pilus profile and lineage, 293 strains from asymptomatic carriers, invasive disease cases,
and bovine mastitis cases, were assessed for biofilm production using an in vitro assay.
Results: Multilocus sequence type (ST) profile, pilus island profile, and isolate source were associated with biofilm
production. Strains from invasive disease cases and/or belonging to the ST-17 and ST-19 lineages were significantly
more likely to form weak biofilms, whereas strains producing strong biofilms were recovered more frequently from
individuals with asymptomatic colonization.
Conclusions: These data suggest that biofilm production is a lineage-specific trait in GBS and may promote
colonization of strains representing lineages other than STs 17 and 19. The findings herein also demonstrate that
biofilms must be considered in the treatment of pregnant women, particularly for women with heavy GBS
colonization.
Background
Group B Streptococcus (GBS), or Streptococcus agalac-
tiae, is a leading cause of neonatal sepsis and meningitis
worldwide [1, 2]. Originally identified as the etiological
agent in bovine mastitis, GBS is present as a commensal
in the gastrointestinal and urogenital tracts in 15–30 %
of healthy adults [3]. Human cases of invasive GBS dis-
ease were reported in the early 1900’s where GBS was
identified as the primary cause of neonatal infections,
with up to a 50 % mortality rate and devastating long
term effects for survivors [4, 5]. GBS is also responsible
for soft tissue infections in the elderly and immunocom-
promised individuals [6]. In most neonatal infections, the
pathogen is vertically transmitted before or during birth,
however, in adults there are implications of transmission
due to exposure to either infected humans or other
animals [7–9]. Understanding the interplay of factors
driving transmission of and persistent infection with GBS
is essential to the development of treatments leading to
the prevention of disease.
Colonization and persistence are critical for GBS-
mediated disease in humans. Guidelines established in
1996 in the United States recommended screening for
maternal colonization during the late third trimester
followed by intrapartum antibiotic prophylaxis of GBS-
positive women during labor [4]. The institution of these
guidelines has resulted in a dramatic decrease in the in-
cidence of neonatal early onset disease (EOD), or cases
within the first week of life. Studies have shown, how-
ever, that re-colonization of the mother occurs in up to
65 % of cases following antibiotic treatment, which may
explain why having a previous baby with invasive GBS
disease is a risk factor for neonatal disease, and no
changes have been reported in the incidence of late on-
set disease (LOD), or infections occurring up to 3
months of age [10–12]. Application of multilocus
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sequence typing (MLST) targeting seven reference genes
has identified specific sequence types (STs) and clonal
complexes (CCs) to be associated with maternal
colonization as well as neonatal disease. CCs 1 and 23, for
instance, have previously been linked to asymptomatic
colonization, while CCs-17 and -19 were found to pre-
dominate among neonates. Nonetheless, differences in CC
distributions have been noted across populations [13–
16] as have risk factors. In addition to complications dur-
ing labor, heavy GBS colonization of the mother was sug-
gested to be a risk factor for neonatal infections and
preterm birth [17], though few studies have explored
whether the density of maternal colonization is linked to
specific bacterial factors.
Several factors have been found to be important for
GBS colonization, the first step in pathogenesis. Proteins
shown to facilitate binding to host cell surface compo-
nents include the laminin-binding protein (Lmb), fibrino-
gen binding proteins (FbsA, FbsB, and ScpB), serine-
repeat rich proteins (Srr-1 and Srr-2), and pili [18–24].
Similarly, the chemical composition and antigenic vari-
ation of the polysaccharide capsule has been linked to
virulence while survivability in different environments and
biofilm formation were also suggested to be important,
particularly in the case of persistent colonization [25–29].
A biofilm is defined as an aggregation of cells in a dis-
tinctly sessile state surrounded by a self-produced matrix
composed of polysaccharide as well as protein and DNA
[30]. For some bacterial pathogens, biofilm production is
an important virulence determinant that has been linked
to colonization and disease progression [30, 31]. Biofilms
offer protection in harsh environments that can include
antimicrobials, extreme pH, and immune cells, thereby
promoting the maintenance of a bacterial population that
can contribute to chronic infection and heavy colonization
[32–35]. The specific environmental conditions found
within biofilms can also exert a selective pressure that can
enhance pathogenicity via the rise of phenotypic and
genotypic variants [35, 36]. Additional information on
GBS biofilms was published in a recent review by Rosini
and Margarit [37]. Previous studies have shown that pili
play an important role in biofilm formation in GBS, and
each GBS genome encodes one or two distinct pilus
islands (PI), PI-1 and PI-2 [20, 38, 39]. PI-1 has been
observed in high frequency among human strains com-
bined with one of two genetically distinct PI-2 variants,
PI-2a and PI-2b [40, 41], yet the effect of PI sequence
diversity on biofilm production has not been addressed.
Because the role of biofilms in GBS-mediated disease is
not known, and this phenotype has been observed to vary
between isolates, we sought to characterize biofilm produc-
tion across strains to identify biofilm determinants includ-
ing isolation source, phylogenetic lineage, and variability in
both presence and sequence of pilus loci [25, 26].
Furthermore, we sought to determine whether allelic vari-
ation within genes encoding the PIs impacts biofilm forma-
tion, as well as attachment to host cells, particularly among
genotypes associated with neonatal disease. Because GBS
pili have been posited as potential vaccination targets due
to their importance in biofilms and adherence to and inva-
sion of host cells, further understanding of allelic diversity
and pilus-associated phenotypes could guide the develop-
ment of new prevention strategies [40].
Results
Source and genotype are predictive of biofilm
phenotypes
Assaying biofilm production in 293 strains, including 242
human and 51 bovine strains resulted in a range of
absorbance values from 0.1 to 12.3 (Fig. 1). Using the
median absorbance value of 1.8 to classify the biofilm
phenotype, 148 (50.5 %) strains were categorized as strong
biofilm producers and 145 (49.5 %) were designated weak
biofilm producers. In all, there was considerable variation
by source with human-derived strains having decreased
levels of biofilm production relative to the bovine-derived
strains. A total of 138 (57.0 %) of the 242 human-derived
strains formed a weak biofilm compared to only six
(11.8 %) of the 51 bovine-derived strains. Indeed, the
bovine strains were significantly more likely to form
strong biofilms relative to the human strains overall (Odds
ratio (OR): 10.0; 95 % confidence interval (CI): 4.09, 24.21;
p < 0.0001). The average absorbance (OD595) for human
strains was 1.7 (range: 0.1 to 5.0), while the average OD595
for bovine strains was 6.3 (range: 0.6 to 12.3). Among
human-derived strains, an association was also observed
by source, as maternal colonizing strains were more likely
to be strong biofilm producers compared to neonatal inva-
sive strains (OR: 1.8; 95 % CI: 1.02, 3.06; p = 0.04). A total
of 45 of the 98 (45.9 %) maternal colonizing strains had a
strong biofilm phenotype relative to only 32.5 % (n = 39)
of the 120 invasive strains from newborns with sepsis or
meningitis.
To examine phenotypic variation by genotypes, biofilm
production levels were compared between STs and CCs
(Fig. 2). Interestingly, the majority (87.3 %) of the weak
biofilm producers belonged to CC-17 and CC-19; 75.7 %
(n = 53) and 79.6 % (n = 70) of the strains belonging to
these two lineages, respectively, were classified as weak.
Although both lineages were overrepresented in the ana-
lysis, it is notable that no other lineages had weak bio-
film producers outnumbering the strong producers.
Among all 158 CC-17 and CC-19 strains combined,
77.8 % (n = 123) formed weak biofilms compared to only
15.6 % of the 135 strains belonging to all other CCs (X2 =
113.0, p < 0.0001). By contrast, the lineages that were
exclusively comprised of bovine strains (e.g., CCs 61 and
67) were most frequently classified as strong biofilm
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producers. Only three strains among all 32 strains repre-
senting CC-61 and CC-67 had weak levels of biofilm pro-
duction. It is important to note that some CCs such as
CC-23 and CC-1, which mostly contained human-derived
strains, also contained a subset of three and four bovine-
derived strains, respectively. After excluding these bovine
strains from the analysis, however, both CCs 23 and 1
were still overrepresented with strong biofilm producing
strains. Similarly, although there was only one representa-
tive of each, the bovine-derived strains representing CC-
17 and CC-19 formed strong biofilms unlike the remain-
der of the strains within these two lineages. When the 51
bovine isolates were compared to 75 human isolates com-
prising the lineages previously associated with asymptom-
atic carriage (e.g., CCs 1, 7, 12, and 23), there was no
significant difference in biofilm phenotype frequencies.
In addition, we examined associations between disease
presentation and biofilm phenotype for 70 (62.5 %) and 42
(37.5 %) isolates recovered from neonates with EOD and
LOD, respectively. These isolates represented CCs 1 (n =
5), 12 (n = 2), 17 (n = 53), 19 (n = 40), and 23 (n = 8) as
well as singletons (n = 4). When all 112 isolates were
examined together, there was no association between bio-
film phenotype and disease onset; however, when stratified
by CC, weak biofilm-formers belonging to CCs 17 and 19
were significantly more likely to cause EOD. Among the
EOD cases, strong biofilm producers belonging to lineages
other than CCs 17 and 19 were 28.7 times more likely to
cause EOD (CI: 6.75, 121.69; p < 0.0001) than strains of
CCs 17 and 19. A similar comparison could not be
examined for LOD cases as all were caused by CC-17
strains in this study.
Biofilm production in GBS is influenced by PI occupancy
and variation in PI genes
Biofilm production varied across strains with different PI
profiles. Strains containing a PI-2 variant alone were
significantly more likely to produce strong biofilms
compared to strains with a PI-2 variant as well as PI-1
(OR: 10.4; 95 % CI: 4.91, 22.00; p < 0.0001). Weak biofilm
production was more common in strains with both PI-1
and either PI-2 variant as 54.9 % of the 142 PI-1/PI-2a-
positive strains and 70.3 % of the 81 PI-1/2b-positive
strains formed weak biofilms. Significantly more PI-1/2b
strains, however, formed weak biofilms compared to the
PI-1/2a strains (OR: 1.9; 95 % CI: 1.09, 3.48; p < 0.02).
Although an equal percentage of strains with exclusively
PI-2a (n = 22; 84.6 %) or PI-2b (n = 39; 88.6 %) were cap-
able of forming strong biofilms (p = 0.63), differences were
noted in the absorbance values (Fig. 3). Specifically, strains
with PI-2a alone had a mean absorbance value of 2.6 ± 1.0
compared to strains with PI-2b alone (6.5 ± 3.2; Mann-
Wilcox test, p ≤ 0.0001). Strains with PI-2a alone also had
a significantly higher mean absorbance value than strains
with both PI-1 and PI-2a (1.9 ± 1.5; Mann-Wilcox test,
p ≤ 0.0001), which also was true for strains containing
both PI-1 and PI-2b (1.5 ± 0.6) relative to those with PI-2b
alone (Mann-Wilcox test, p ≤ 0.0001). Because all strains
with PI-2b alone were recovered from bovines, a
Fig. 1 Source, frequency, and strength of biofilm production among 293 group B streptococcal strains by biofilm absorbance (OD595). Bar height
represents the percentage of isolates within each absorbance category listed on the x-axis. Strong biofilm producers were classified as having an
OD595 of 1.8 or greater
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Fig. 2 (See legend on next page.)
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comparison could not be made between PI-2b- and PI-2a-
positive strains from humans.
To examine the association between genetic variation
in PI genes and biofilm formation, we stratified biofilm
strength by alleles detected in gbs59, the ancillary pilus
protein in PI-2a, and san1519, the PI-2b adhesin. Vari-
able biofilm production levels were observed among
strains with different alleles of both genes. For gbs59, six
alleles were identified and five of these six alleles (alleles
2-6) were significantly more common in strong biofilm
producers (OR: 20.6; 95 % CI: 9.27, 45.62; p ≤ 0.0001).
Only the gbs59 allele 1, which predominated in 89 of the
168 PI-2a-positive strains, was more frequently detected
in strains that formed weak biofilms (Table 1). The
majority (n = 87; 97.8 %) of strains containing gbs59
allele 1 belonged to CC-19, and more of these strains
were recovered from neonates (n = 45; 52 %) than preg-
nant women (n = 39; 44.8 %); one strain originated from
a bovine. Indeed, the neonatal CC-19 strains containing
the gbs59 allele 1 were significantly less likely to form
strong biofilms relative to the maternal CC-19 strains
with other alleles (p ≤ 0.02). Similar findings were ob-
served for PI-2b, which were predominantly represented
by CC-17. Strains with san1519 allele 2 were signifi-
cantly more likely to form weak biofilms relative to
strains with san1519 alleles 1 and 3 (OR: 17.3; 95 % CI:
6.99, 42.81; p ≤ 0.0001). No difference in frequency was
observed for CC-17 strains with san1519 allele 2
between neonates and pregnant women (Fisher’s exact
p ≤ 1.0). Among the 32 bovine strains with san1519 allele
3 from the bovine specific lineages, CCs 61 and 67, most
(n = 29; 90.6 %) formed strong biofilms.
Multivariate analysis identifies source and genotype as
important predictors of enhanced biofilm production
To further identify predictive features of strong biofilm
production in GBS, we conducted a multivariate analysis
including the following variables: pilus profile, source,
and genotype. Among all GBS strains examined, only
bovine source was moderately associated with strong
biofilm production (OR: 3.6; 95 % CI: 0.92, 13.80; p =
0.07). A positive association was observed for the pres-
ence of PI-2a, but it was also not statistically significant
(OR: 2.7; 95 % CI: 0.75, 9.90; p = 0.13) when adjusted for
strain source and genotype. After excluding bovine
strains from the analysis (Table 2), the presence of PI-2a
remained associated with strong biofilm production;
however, the association was still insignificant. Import-
antly, strains representing both CCs 17 and 19 were
significantly less likely to form strong biofilms after
controlling for source (invasive versus colonizing) and
(See figure on previous page.)
Fig. 2 Variation in biofilm production among group B Streptococcus strains representing distinct phylogenetic lineages. The Neighbor-joining phyl-
ogeny grouped the 73 sequence types (STs) into eight clonal complexes (CCs), which are represented with different colors. Bovine strains are indicated
in red and the frequency (%) of strains forming a strong (dark grey) versus weak (light grey) biofilm is shown within each CC as individual pie charts
Fig. 3 Biofilm absorbance among group B streptococcal strains with different pilus island (PI) profiles. Center line of boxes is average absorbance,
boxes represent the middle two quartiles, and whisker bars represent highest and lowest quartiles
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presence of PI-2a relative to other PI combinations.
Unlike the univariate analysis, strains belonging to CCs
1 and 23 were not more likely to produce strong bio-
films in the multivariate analysis.
The CC-17 lineage displays decreased association with
Telomerase-immortalized Human Endothelial Cells
(T-HESCs)
Variation in the ability to associate with decidualized T-
HESC was observed among the 32 strains chosen to
represent CCs 1, 17, and 23 with different biofilm pheno-
types. The 16 CC-17 strains evaluated had T-HESC
attachment levels between 0.003 and 0.199 % with an
average of 0.062 ± 0.048 %. The eight CC-1 strains had
slightly greater association levels to T-HESC (0.015 to
1.145 %) than the CC-17 strains, whereas association
levels for the eight CC-23 strains were highly variable
(range: 0.004 to 21.68 %). Interestingly, association with T-
HESCs by CC-17 strains was significantly decreased when
compared to both CCs 1 and 23 combined with averages
of 0.057 and 0.245 %, respectively (Mann-Wilcox test, p-
value < 0.0005) (Fig. 4a). After stratifying association levels
by biofilm production, no difference was observed within
or between lineages. When source was considered, how-
ever, CC-17 strains from invasive disease cases associated
with T-HESCs at higher levels than CC-17 maternal
colonizing strains, with averages of 0.077 and 0.037 %,
respectively. (Mann-Wilcox test, p-value <0.03) (Fig. 4b).
Discussion
Because colonization of the host, or mother in the case of
neonatal infection, is currently the primary predictor of
GBS transmission and subsequent disease development
[3, 42], we examined biofilm production in strains recov-
ered from patients with invasive disease, individuals with
asymptomatic colonization, and bovines with mastitis.
Through this study we have demonstrated that biofilm
production varies considerably across this diverse set of
GBS strains. The phenotypic variation observed is in
accordance with previous studies reporting OD595 values
ranging from < 0.1 to >12 for GBS and other pathogens
[25, 26, 43–45]. The OD595 value of 1.8 was used to distin-
guish between weak and strong biofilm production. This
value is more conservative and higher than the OD595
values of 0.5 and 0.65 used in two prior studies with a
similar biofilm assay, but it is lower than the value of 3.0
used in another study with a modified assay [25, 26, 46].
In our study, the distribution of OD595 values was not
bimodal and hence, the 1.8 cut-off value was used to
optimize sensitivity and specificity for the classification of
weak versus strong biofilm producers. It is important to
note, however, that any cut-off value carries a degree of
subjectivity. In addition, differences between studies may
be due to the media or type of plates used for the assays
as both can alter the strength of a developing biofilm. In
our study, we used THB plus 1 % glucose and tissue-
culture treated polystyrene plates compared to TSB or
untreated polystyrene plates in other studies [26, 46].
Table 1 Frequency of strong biofilm production among strains with distinct pilus island (PI) alleles and PI-1
Pilus island allele (a) Total number of strains Strong biofilm (%), n Clonal complexes represented (n) PI-1 presence (%)
PI-2a, a1 89 21.4 (n = 19) 19 (n = 87), 1 (n = 1), 12 (n = 1) 98.9
PI-2a, a2 16 87.5 (n = 14) 23 (n = 8), 1 (n = 7), S (n = 1) 93.8
PI-2a, a3 5 100.0 (n = 5) 12 (n = 3), 1 (n = 1), 7 (n = 1) 60.0
PI-2a, a4 6 83.3 (n = 5) S (n = 5), 1 (n = 1) 66.7
PI-2a, a5 21 90.5 (n = 19) 23 (n = 17), S (n = 2), 19 (n = 1), 7 (n = 1) 14.3
PI-2a, a6 31 77.4 (n = 24) 1 (n = 17), 12 (n = 9), 23 (n = 4), S (n = 1) 93.6
PI-2b, a1 11 72.7 (n = 8) 1 (n = 8), 7 (n = 2), S (n = 1) 100.0
PI-2b, a2 69 21.7 (n = 16) 17 (n = 69) 100.0
PI-2b, a3 45 86.7 (n = 39) 61 (n = 20), 67 (n = 12), S (n = 11), 1 (n = 1), 17 (n = 1) 2.2
S singleton
Table 2 Multivariate analysis of characteristics associated with
strong biofilm production in human-derived strains
Characteristics Adjusted ORa (95 % CI) p-value*
Pilus Island (PI)
Other PI combinations 1.0 –
PI-2a presence 4.0 (0.85,19.02) 0.08
Clonal complexes (CCs)
Other CCs 1.0 –
CC-1 0.7 (0.18, 3.02) 0.66
CC-23 1.0 (0.19, 5.46) 0.99
CC-17 0.2 (0.03, 1.01) 0.05
CC-19 0.04 (0.01, 0.14) <0.0001
Strain source
Asymptomatic colonization 1.0 –
Invasive disease 1.2 (0.57, 2.33) 0.68
aOR odds ratio, 95 % CI 95 % confidence interval
*Walds Chi-square test
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Because all strains were examined in similar conditions,
our results are internally comparable, though external
comparisons cannot be reliably made to data generated in
other studies. It is important to note that we also assessed
biofilm production in a subset of strains in other condi-
tions including THB without glucose and in differing pHs
as well as in the T-HESC infection media. The same
trends were observed between isolates in these conditions,
though the absorbance values were lower overall (data not
shown).
Among all 293 strains examined, those strains origin-
ally recovered from bovines were capable of forming the
strongest biofilms relative to the strains isolated from
humans. Because there was no difference in biofilm
phenotypes between strains representing the colonizing
human lineages and the bovine lineages, these data
suggest that strong biofilm production is more import-
ant for colonization in humans and bovines when com-
pared to neonatal disease. It is therefore possible that
unique genes or allelic variation within specific genes
present in the bovine and human colonizing lineages,
but lacking in invasive human strains, are important for
biofilm phenotypes [47]. For example, we found that the
human-derived strains possessing both PI-1 and either
PI-2 variant had reduced biofilm production compared
to those strains without PI-1. These data suggest an in-
hibitory effect of PI-1, an operon encoding a specific pi-
lus type that is absent in bovine-derived strains
belonging to the bovine-specific lineages [41]. Although
a previous study found no effect on biofilm production
in a PI-1 knockout [46], only one serotype Ia GBS strain
was examined. Hence, it is possible that strains with
varying genetic backgrounds, such as those belonging to
CC-17 or CC-19 may behave differently when PI-1 is de-
leted. Similar to findings from a prior study [46], allelic
variation within the genes comprising each PI may con-
tribute to variation in the level of biofilm production ob-
served. We found that specific alleles of gbs59 and
san1519 were linked to strong biofilm formation while
san1519 allele 2, found exclusively in CC-17 strains, was
associated with weak biofilm production. Since san1519
allele 3 was restricted to the bovine strains [41], then this
may also explain the association with strong biofilms. Des-
pite these associations, future studies should focus on
assessing the role of sequence variation on pili functional-
ity and biofilms as other factors unique to specific lineages
are also likely to be important. Given the proposed devel-
opment of pilus-based vaccines for the treatment of GBS-
mediated disease, these data highlight the importance of
considering sequence variation in future vaccine develop-
ment efforts similar to pilus-based vaccines targeting fim-
briae in Escherichia coli and Salmonella enterica.
Another possible explanation for the increased biofilm
production of the bovine-derived lineages is the presence
of the lactose metabolism operon, Lac.2. This operon
has been detected in the majority of bovine genomes,
and upregulation of genes within the operon as well as
genes important for glucose metabolism, have been
documented following growth in milk [47, 48]. A prior
study of Streptococcus mutans demonstrated enhanced
biofilm production in the presence of lactose, a key com-
ponent of milk [49]. Although it is possible that the
ability to metabolize lactose and form strong biofilms is
important for GBS survival in the bovine mammary
gland to counteract the regular flow of milk, our in vitro
biofilm assays were conducted without the addition of
lactose. These data therefore suggest that other genes or
gene combinations are more important for biofilm pro-
duction in vitro. A prior study conducted by Ebrahimi et
al. [50] also showed biofilm production to be a common
Fig. 4 Variation in bacterial association with decidualized T-HESC.
Percent association among a) 32 strains representing distinct
phylogenetic lineages or clonal complexes (CCs); and b) 16 strains
belonging solely to CC-17 by source. Individual data points represent
the average of three experiments with the largest horizontal lines and
error bars representing the mean of data points and standard
deviations, respectively
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feature of bovine strains in vitro, and hence, future stud-
ies should focus on mutagenesis of genes unique to bo-
vine strains to determine their impact on biofilm formation
and disease development in vivo.
In contrast to the consistently strong levels of biofilm
production observed for the bovine strains, biofilm levels
were highly variable between human-derived strains.
Despite this variation, we found that strains of CC 17
and 19, the two CCs most commonly associated with
invasive neonatal disease [14, 15], had significantly de-
creased levels of biofilm production compared to other
CCs even after adjusting for PI profile and source. Like-
wise, we identified increased biofilm production in all
but one of the bovine-derived strains representing line-
ages that were previously associated with asymptomatic
carriage in humans [14]. Although the latter associations
were less clear in the multivariate model, these findings
indicate a correlation between weak biofilm production
and increased pathogenicity. Furthermore, strains from
neonates with invasive disease were more likely to form
weak biofilms compared to colonizing strains recovered
from pregnant women, which is a similar trend as was
reported previously [26]. When disease onset was taken
into account, weak biofilm production was associated
with EOD exclusively for strains belonging to CCs 17
and 19, while neonates with EOD caused by strains
belonging to lineages other than CC-17 and CC-19 were
significantly more likely to produce strong biofilms.
These data suggest different roles for biofilm formation
in colonization and disease among the lineages. Because
maternal transmission is frequently implicated in cases
of EOD, strong biofilm production in the less virulent
lineages may result in the transmission of greater bacter-
ial densities. More studies, however, are needed to assess
the role that biofilms play in both EOD and transmis-
sion. The association between weak biofilm production
and invasive disease across all isolates is in accordance
with results in Streptococcus pneumoniae, which demon-
strated decreased pathogenicity in biofilm-associated cells
explained by an altered transcriptome favoring colonization
over invasiveness [51]. While our assay assessed optimal
biofilm production in vitro, the plasticity of this trait due to
environmental conditions encountered during colonization
and pathogenesis was not explored. It remains possible that
the biofilm production reported here may not reflect the
ability of specific isolates to form biofilms in every environ-
ment. The elucidation of conditions that may trigger
attachment and biofilm production is critical to determine
the role of GBS biofilms in disease and colonization.
Decreased biofilm production within CC-17 and -19
strains is interesting given the protection conferred to
biofilm-associated bacteria and the prior finding that these
two lineages persisted better in women despite antibiotic
treatment [11]. It is therefore possible that weak biofilm
producers belonging to CCs 17 and 19 utilize different
environmental cues to induce biofilm formation, or have
distinct persistence strategies that do not rely on biofilms.
In support of the former, a prior study found that expos-
ure to acidic pH was an important factor for biofilm
production by a subset of isolates belonging to ST-17 [25].
Because we observed no difference in T-HESC association
levels between strong and weak biofilm producers overall,
it is likely that biofilms are less important for host cell
association. Biofilms take longer to form and cannot be
reliably examined in these tissue culture assays, yet we
expect that strong biofilm producers will have higher
attachment levels and bacterial densities over time and
hence, have a colonization advantage. We also expect
these densities to vary across environments, genotypes,
and individual isolates as was shown in our prior study
between two CC-17 strains [52]. Indeed, it is possible that
invasion of host cells is critical for strains that are not
capable of forming strong biofilms, which may be more
apparent in vivo. Although invasion frequencies were not
calculated in this study, we expect them to be low given
our prior findings [52] and importantly, differences would
still be detectable using cell association frequencies that
includes both the attached and invaded bacterial popula-
tions. These data are also in line with the epidemiological
associations observed between CC-17 strains and invasive
disease [14, 15] and our observation that invasive CC-17
strains had higher association levels compared to the col-
onizing CC-17 strains.
Together, these data highlight the phenotypic variabil-
ity among GBS strains and support the hypothesis that
strategies other than biofilm production are important
for initial host cell attachment and persistence in some
strains. Identifying alternative strategies requires further
study, though variation in the ability to evade or survive
within immune cells, invade the epithelia, and tolerate
antibiotics, are all likely to be important. For those GBS
strains that are capable of forming strong biofilms and
also have enhanced association with host cells, it is
possible that similar adherence mechanisms are used for
each process. These mechanisms are likely to vary across
genotypes and could be attributable to variation in differ-
ent combinations of undefined or well-known surface
proteins such as Lmb, Fbs, ScpB, Srr, and pili [18–24].
Indeed, strains from colonizing lineages have been shown
to contain greater genetic diversity than invasive lineages
like CC-17, which is well represented in our data, as
variability in both biofilm production and host cell attach-
ment was higher in colonizing lineages [53–55]. The ob-
served differences in association levels between invasive
and colonizing CC-17 strains, however, also suggest that
variation between CC-17 strains exists. Additional studies
are therefore needed to define the specific mechanisms of
host cell attachment as well as biofilm production in
Parker et al. BMC Microbiology  (2016) 16:86 Page 8 of 12
diverse GBS strain populations; such studies will facilitate
the identification of unique therapeutic or vaccine targets.
Furthermore, because biofilms confer protection from
antibiotics and immune system effectors, and contribute
to the development of chronic infections in multiple
bacterial pathogens, these findings posit biofilm produc-
tion in GBS as clinically important for colonization in
lineages other than CCs 17 and 19. Despite the generally
weak biofilm production observed in disease-associated
lineages, GBS colonization is an important risk factor for
neonatal infections as well as opportunistic infections in
susceptible individuals regardless of bacterial genotype.
Hence, eradicating or thwarting biofilm production should
be considered in the development of novel treatment and
prevention strategies for GBS-mediated diseases.
Conclusions
Quantifying biofilm production among 293 GBS strains
from diverse sources demonstrated variation in the ability
to form strong biofilms among strains belonging to differ-
ent genotypes and from distinct sources. Those strains
originating from bovines were capable of forming strong
biofilms relative to strains from humans, though invasive
versus colonizing human-derived strains belonging to CCs
17 and 19 were more likely to produce weak biofilms.
Specific PI profiles and allelic variation within PI genes
were also important for strong biofilm production, but no
difference was observed in the ability of strong and weak
biofilm producers to associate with T-HESCs. In all, these
findings suggest that biofilm production is important for a
subset of GBS strains and should be considered in the
treatment of GBS-positive pregnant women to limit trans-
mission to newborns.
Methods
Bacterial strains
A total of 293 GBS strains representing 73 STs and eight
CCs were characterized in this study. A complete list of
the strains evaluated can be found in Additional file 1:
Table S1. Most strains were recovered from the blood or
cerebral spinal fluid of neonates (invasive strains; n = 120)
or vaginal/rectal swabs of pregnant women (colonizing
strains; n = 88). Approval to characterize the de-identified
bacterial isolates was provided by both the University of
Calgary Ethics Board and Michigan State University Insti-
tutional Review Board. For comparison, 51 strains from
quarter milk samples previously recovered from bovines
with clinical or subclinical mastitis were characterized
[56] and a reference set of 35 human-derived strains of
varying STs and serotypes was included to compare
biofilm production across phylogenetically distinct line-
ages. Reference strains included genome and control
strains (n = 14) as well as ten strains each from adults with
invasive disease and non-pregnant women. Except where
otherwise indicated, GBS cultures were grown overnight
in Todd-Hewitt (TH) broth at 37 °C with 5 % CO2. Strains
were previously characterized for the PI type and allelic
variation within the PI-2a backbone protein gene (gbs59)
and the PI-2b adhesin gene (san1519) [41].
Biofilm assays
Overnight cultures inoculated from freezer stocks were
grown in TH broth, and then diluted 1:20 in fresh TH
supplemented with 1 % glucose (THG). A total of 100 μl
of the diluted culture was added to a 96-well plate with
four technical replicates per strain. Cells were grown
under static conditions at 37 °C with 5 % CO2 for 20 h.
Following incubation, unattached bacteria were removed
by washing twice with Phosphate Buffered Saline (PBS)
(200ul), and attached bacteria were stained with 100 μl
crystal violet for 10 min. Unbound crystal violet was
removed by washing three times with PBS, and bound
crystal violet was solubilized with 200 ul of 95 % ethanol.
Biofilm production was quantified through absorbance
readings (OD595) using a plate reader (Beckman Coulter,
Inc.) and measurements were calculated as the sample
value minus the media (blank) control. All assays were re-
peated at least three times with at least three technical
replicates. All OD595 values above 1.8, the median value of
all strains tested, represented strains that produce a strong
biofilm. To determine this cutoff value, absorbance values
were log-transformed and found to pass the D’Agostino
and Pearson test of normality [57]. Chi-square (χ 2) and
the Fisher’s Exact test for sample sizes less than five were
used to examine associations with biofilm production
(weak versus strong) using SAS (version 9.3); a P-value <
0.05 was considered significant. Odds ratios (OR) and
95 % confidence intervals (95 % CI) were calculated to
describe the univariate relationships. Multivariate analyses
were conducted using logistic regression to identify pre-
dictors of strong biofilm production among the human-
derived strains.
Association with telomerase-immortalized human
endometrial cells (T-HESC)
T-HESCs were decidualized as previously described [58]
by growing the cells to ~50 % confluence and treating
with 0.5 mM 8-bromo-cAMP (Sigma-Aldrich; St. Louis,
MO) for three to six days. Decidualization was confirmed
by examining the expression of prolactin and insulin-like
growth factor (IGF) binding protein 1. Assays were not
performed until the cells reached 100 % confluency; no
part of the bottom of the well was exposed to avoid
attachment of bacteria to the plastic plates. GBS strains
were selected for testing based on phylogenetic lineage
(CC) and biofilm phenotype with equal representation of
weak and strong biofilm producers for each CC tested. An
equal number of strains from cases of invasive disease and
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asymptomatic colonization were also evaluated when
possible.
Bacterial strains were grown overnight in TH broth,
washed once with PBS and resuspended in T-HESC infec-
tion medium, as previously described, except infecting
inoculums were taken directly from overnight growth
[52]. Host cells were washed three times with PBS prior to
adding GBS at a multiplicity of infection (MOI) of one
bacterial cell per host cell. After a 2 h incubation at 37 °C
with 5 % CO2, 100 μL of supernatant was removed and
serial diluted to determine final bacterial growth. Wells
were then washed three times with PBS to remove non-
adherent bacteria. To determine the number of associated
bacteria, host cells were lysed with 0.1 % Triton X-100
(Sigma) for 30 min at 37 °C. Lysates were gently vortexed
to further disrupt the host cells and liberate intracellular
bacteria. After serial dilution, lysates were plated on THA,
incubated overnight at 37 °C, and colony forming units
(CFUs) were counted. All data were expressed as a per-
centage (number of associated divided by the total num-
ber of bacteria) after the two hour infection period.
Individual assays were run in triplicate and each strain
was tested at least three times.
Additional file
Additional file 1: Strains examined in this study. (XLSX 27 kb)
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